Ethical considerations in phase II trials

May 9, 2013

In an article appearing in the May 8 edition of Science Translational Medicine, Spencer Phillips Hey, Ph.D., a postdoctoral fellow in the Biomedical Ethics Unit at McGill University, and Jonathan Kimmelman, Ph.D., of the Studies for Translation, Ethics, and Medicine Group (STREAM), Biomedical Ethics Unit, McGill University point out the potential ethical and social trade-offs resulting from clinical trial reforms aimed at boosting Phase II positive predictivity. (Genetic Engineering & Biotechnology News)